Bangkok Lab and Cosmetic PCL
SET:BLC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
CuriosityStream Inc
NASDAQ:CURI
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (16.8), the stock would be worth ฿3.82 (1% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 17 | ฿3.88 |
0%
|
| 3-Year Average | 16.8 | ฿3.82 |
-1%
|
| 5-Year Average | 16.8 | ฿3.82 |
-1%
|
| Industry Average | 12.2 | ฿2.79 |
-28%
|
| Country Average | 6.6 | ฿1.51 |
-61%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
B
|
Bangkok Lab and Cosmetic PCL
SET:BLC
|
2.3B THB | 17 | 13.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 52.1 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 23 | 26.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP | 21.3 | 30.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.2 | 19.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 14.8 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 17.9 | 16.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 907.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.7 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 13.4 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 8.6 | 17.2 |
Market Distribution
| Min | 0.4 |
| 30th Percentile | 4.3 |
| Median | 6.6 |
| 70th Percentile | 9.7 |
| Max | 13 115.6 |
Other Multiples
Bangkok Lab and Cosmetic PCL
Glance View
Bangkok Lab & Cosmetic PCL engaes in the provision of pharmaceuticals and health products. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2023-06-21. The firm is engaged in the production of medicines and health products by selecting raw materials. The firm has produced more than 100 products. Its products include ZENZERA 200 SUSPENSION, ZENZERA, SYNOVAR UC40, RADIARA, PROCEMINE, FANGO-B, EMBLICOF COUGH MIXTURE, CLINIGEL STERILE, RAQUA FIBROTA, RAQUA COLLAGEN, SYNOVAR UC, SYNOVAR POWDER, NACOXIB, LUTI-BERRY MIXED, ZIGA GEL (orange), ZERTINE SYRUP, VIZO Cream, SPORAXYL CREAM, NORAPHEN, MURHINOL-250 SYRUP, NORFLOXYL 400, NOCID, MURHINOL-250 SYRUP, MUCOBROX, GYNOSTEN CREAM, and GYNOSTEN 500, AROTIKA COOL GEL, ALLERAX-FC, AROTIKA RUB LOTION (SPRAY), Calza c Dietary Supplement, Calza PLUS POWDER Dietary, and Calza-750 TAB FC, among others. Its products are distributed through Bangkok Drug Co., Ltd., Beereach (Thailand) Co., Ltd., Pharmaline Company Limited, Pharma Alliance Company Ltd., and Bangkok Medica Co., Ltd.
